Focal adhesion kinase (FAK) has been implicated in the development of cancers, including those of the breast. Nevertheless, the molecular and cellular mechanisms by which FAK promotes mammary tumorigenesis in vivo are not well understood. Here, we show that targeted deletion of FAK in mouse mammary epithelium significantly suppresses mammary tumorigenesis in a well-characterized breast cancer model. Ablation of FAK leads to the depletion of a subset of bipotent cells in the tumor that express both luminal marker keratin 8/18 and basal marker keratin 5. Using mammary stem/progenitor markers, including aldehyde dehydrogenase, CD24, CD29, and CD61, we further revealed that ablation of FAK reduced the pool of cancer stem/progenitor cells in primary tumors of FAK-targeted mice and impaired their selfrenewal and migration in vitro. Finally, through transplantation in NOD-SCID mice, we found that cancer stem/progenitor cells isolated from FAK-targeted mice have compromised tumorigenicity and impaired maintenance in vivo. Together, these results show a novel function of FAK in maintaining the mammary cancer stem/progenitor cell population and provide a novel mechanism by which FAK may promote breast cancer development and progression. [Cancer Res 2009;69(2):466-74]
Opiate abuse causes adaptive changes in several processes of synaptic transmission in which the glutamatergic system appears a critical element involved in opiate tolerance and dependence, but the underlying mechanisms remain unclear. In the present study, we found that glutamate uptake in hippocampal synaptosomes was significantly increased (by 70% in chronic morphine-treated rats) during the morphine withdrawal period, likely attributable to an increase in the number of functional glutamate transporters. Immunoblot analysis showed that expression of GLT1 (glutamate transporter subtype 1) was identified to be upregulated in synaptosomes but not in total tissues, suggesting a redistribution of glutamate transporter expression. Moreover, the increase in glutamate uptake was reproduced in cultured neurons during morphine withdrawal, and the increase of uptake in neurons could be blocked by dihydrokainate, a specific inhibitor of GLT1. Cell surface biotinylation and immunoblot analysis showed that morphine withdrawal produced an increase in GLT1 expression rather than EAAC1 (excitatory amino acids carrier 1), a neuronal subtype, at the cultured neuronal cell surface, whereas no significant change was observed in that of cultured astrocytes. Electron microscopy also revealed that GLT1 expression was markedly increased in the nerve terminals of hippocampus and associated with the plasma membrane in vivo. These results suggest that GLT1 in hippocampal neurons can be induced to translocate to the nerve terminals and express on the cell surface during morphine withdrawal. The translocation of GLT1 at synapses during morphine withdrawal provides a neuronal mechanism for modulation of excitatory neurotransmission during opiate abuse.
Rab1a is a member of the Rab family of small GTPases with a well characterized function in the regulation of vesicle trafficking from the endoplasmic reticulum to the Golgi apparatus and within Golgi compartments. The integrin family heterodimeric transmembrane proteins serve as major receptors for extracellular matrix proteins, which play essential roles in cell adhesion and migration. Although effects on intracellular trafficking of integrins or other key cargos by Rab1a could influence cell migration, the regulatory mechanisms linking Rab1a to cell migration are not well understood. Here, we report identification of Rab1a as a novel regulator of cell migration using an unbiased RNAi screen targeting GTPases. Inhibition of Rab1a reduced integrin-mediated cell adhesion and spreading on fibronectins, reduced integrin 1 localization to lipid rafts, and decreased recycling of integrin 1 to the plasma membrane. Analysis of Rab1a effector molecules showed that p115 mediated Rab1a regulation of integrin recycling and lipid raft localization in cell migration. Taken together, these results suggest a novel function for Rab1a in the regulation of cell migration through controlling integrin 1 recycling and localization to lipid rafts via a specific downstream effector pathway.
Background: FAK has both kinase and scaffolding functions. Results: Disruption of the function of FAK scaffolding to mediate endophilin A2 phosphorylation inhibits mammary tumor growth and metastasis in vivo by decreasing tumor cell markers for EMT and their MaCSCs activities. Conclusion:The function of FAK scaffolding is important for promoting mammary tumor progression. Significance: Targeting the scaffolding function of FAK may be important in breast cancer therapy.
Cancer stem cells (CSCs) 2 are proposed to play important roles in the initiation and progression of breast and several other cancers recently (1-4). According to the CSC concept, although the conventional therapies could destroy the bulk of the tumor mass, even a small amount of residual CSCs could lead to recurrence of the cancer due to their stem cell-like ability for self-renewal and differentiation (2). Several recent studies also suggested that CSCs, such as mammary cancer stem cells (MaCSCs), are more resistant to conventional cancer therapies compared with the bulk of cells in the tumor mass (5-9), which could further decrease the effectiveness of conventional cancer treatment strategies. Therefore, the characterization of key signaling molecules and pathways that regulate MaCSCs will be important for understanding mammary carcinogenesis and development of more effective therapeutic strategies for breast cancer through targeting MaCSCs.Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase that plays a major role in mediating signal transduction by integrins as well as growth factor receptors in the regulation of cell adhesion, migration, survival, proliferation, and differentiation in a variety of cells (10 -14). Upon its activation by integrin-mediated cell adhesion or other stimuli, FAK undergoes autophosphorylation at Tyr 397 to create a binding site for several Src homology 2 domain-containing molecules, including Src (15, 16) and the p85 subunit of PI3K (17, 18). FAK association and activation of PI3K through autophosphorylated Tyr 397 leads to increased production of 3Ј-phosphorylated phospholipid (17), which activates Akt to promote cell survival by regulating several other proteins (19 -23). Consistent with its role in regulation of multiple signaling pathways, FAK has been implicated in the development of breast cancer and other malignancies (24,25). Recent studies by several groups, including us, showed that ablation of FAK suppressed mammary tumorigenesis and progression in mouse models of breast cancer, demonstrating directly a causal role of FAK in promoting breast cancer in vivo (26 -29). Moreover, using a combination of well characterized markers and tumorsphere formation assays (30 -34) as well as transplantation experiments, our previous study revealed that inactivation of FAK reduced MaCSCs in primary tumors developed in FAK conditional KO mice, decreased their self-renewal and migration in vitro, and compromised their tumorigenicity and maintenance in vivo (28). These results suggest that deletion of FAK may suppress mammary tumorigenesis and progression by affecting MaCSCs. Nevertheless, it is not clear which of the multiple FAK downstream signaling pathways mediate its regulation of MaCSCs. The potential mechanisms that allow mammary tumorigenesis and metastasis in FAK conditional KO mice, albeit at a reduced level, are not well understood.Pyk2 is the other member of the FAK subfamily cytoplasmic tyrosine kinases that shares significant sequence homology and
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.